Head-to-head evidence
JR-131 vs NNG-DEPO
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: Erythropoietin receptor (EPO-R) · full Chronic Kidney Disease pipeline
JR-131
Developed by Kissei Pharmaceutical
NCT02912494 · Phase 3 · completed
The study was double-blind and used an active darbepoetin alfa comparator, but the registry does not state whether participants were randomized or report the sample size. Its primary endpoint was change in hemoglobin, a surrogate measure. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
NNG-DEPO · Stimus
Developed by Nanogen Pharmaceutical Biotechnology
NCT05585645 · Phase 3 · completed
The trial was randomized, double-blind, and actively controlled with Aranesp, enrolling 214 participants. However, its primary endpoint was a hemoglobin change measure rather than a hard clinical outcome, and no primary comparison results are available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: JR-131's landscape · NNG-DEPO's landscape